GILD announced a cash dividend of 0.75 with an ex-date of Dec. 14, 2023
|Bid||80.09 x 1100|
|Ask||80.10 x 800|
|Day's Range||79.47 - 80.84|
|52 Week Range||72.87 - 89.74|
|Beta (5Y Monthly)||0.31|
|PE Ratio (TTM)||17.15|
|Forward Dividend & Yield||3.00 (3.80%)|
|Ex-Dividend Date||Dec 14, 2023|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for GILD
On Nov. 28, the Food and Drug Administration (FDA) announced that it was opening an investigation into the possibility of previously unknown serious safety risks associated with the hottest and most technological group of cancer medicines produced to date. Now, drugmakers including Novartis (NYSE: NVS), Gilead Sciences (NASDAQ: GILD), and Bristol Myers Squibb (NYSE: BMY) are on the hot seat, with their patients' well-being and billions of dollars in revenue on the line. The FDA is concerned about chimeric antigen receptor T-cell (CAR T-cell) therapies.
Readers hoping to buy Gilead Sciences, Inc. ( NASDAQ:GILD ) for its dividend will need to make their move shortly, as...
In the latest trading session, Gilead Sciences (GILD) closed at $79.02, marking a +1.24% move from the previous day.